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Abstract: Human papillomavirus type 16 (HPV16) is the primary etiologic agent for greater than 50% of all cervical car-
cinomas. Expression of the HPV16 E6 and E7 oncoproteins is under control of the upstream regulatory region (URR), 
which contains a myriad of transcription factor binding sites, including 7 half sites for NFI. These NFI binding sites were 
used as probes in electrophoretic mobility shift assays (EMSAs), and mutational analysis of individual and multiple NFI 
binding sites was performed in order to demonstrate the relative importance of particular NFI sites to URR activity. By 
using 5 NFI half sites as an enhancer, we were able to detect a 4-fold increase in URR activity. Our results define the role 
and relative contribution of NFI binding sites to the basal activity of the HPV16 promoter, and demonstrate that NFI bind-
ing sites can act independently to enhance HPV16 URR activity in immortalized keratinocytes. 
INTRODUCTION 
  Human papillomaviruses (HPVs) are responsible for be-
nign and malignant epithelial lesions such as common warts, 
genital warts, and cervical cancer [1]. High-risk HPVs are 
associated with nearly all cervical carcinomas, and HPV 
Type 16 (HPV16) is by far the most prevalent of the high-
risk types [2]. The majority of HPV-associated lesions do not 
progress to cervical carcinoma, as they are inhibited by mul-
tiple mechanisms such as transcriptional repression of the 
HPV early genes, including the E6 and E7 oncogenes. High-
risk HPV E6 and E7 oncoproteins play a significant role in 
malignant conversion of infected cutaneous epithelial and 
mucosal cells [3-6]. Since expression of the HPV E6 and E7 
oncoproteins is controlled by the upstream regulatory region 
(URR), transcriptional control of the high-risk HPV URRs 
(such as HPV16, 18 and 31) has been the focus of numerous 
studies. 
  HPV early gene expression is controlled by a complex 
interaction of cellular and viral factors that bind to the URR, 
which contains a myriad of transcription factor binding sites, 
including 7 half sites for nuclear factor I (NFI). NFI, AP-1, 
Oct-1, Tef-1, Tef-2, and the progesterone / glucocorticoid 
receptor all bind and act synergistically to promote viral 
transcription through the HPV URR [7-13]. 
  NFI is a family of site-specific DNA-binding factors that 
function both in viral DNA replication and in the control of 
viral and cellular gene expression [14]. We have previously 
demonstrated that NFI binding sites within the HPV16 URR 
are critical for TGF-ß modulation of URR activity [15].   
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While mutational analysis has been performed on several 
NFI binding sites in the HPV16 URR [16, 17], demonstrat-
ing the importance of the NFI transcription factor to HPV16 
URR activity, a complete mutational analysis of all 7 NFI 
sites has not been previously reported. 
  The main goal of this study was to explore how much 
each of the 7 NFI binding sites in the HPV16 URR contrib-
utes to overall promoter activity. We also sought to deter-
mine whether NFI could function as an enhancer of URR 
activity in the absence of other URR transcription factor 
binding sites. 
MATERIALS AND METHODS 
  Cell Culture and Cell Lines. Normal human keratino-
cytes (HKc) were isolated from neonatal
 foreskins and im-
mortalized by transfection with a plasmid containing
 a head-
to-tail dimer of HPV16 DNA (HKc/HPV16) and cultured in 
serum-free MCDB153-Luria-Bertani basal medium supple-
mented
 with 5 ng of epidermal growth factor/ml, 35 to 50 g 
of
  bovine pituitary extract protein/ml, 0.2 M hydrocorti-
sone,
 0.1 mM calcium chloride, 10 nM triiodothyronine, 10 
g
 of transferrin/ml, and 5 g of insulin/ml (complete me-
dium), as described previously [15]. Cells were split 1:10 
when
 confluent, and medium was replaced every 48 h.
 
 Nuclear  Extracts. HKc/HPV16 were grown to 40 to 
50% confluency in 100-mm-diameter
  tissue culture plates. 
Nuclear extracts were obtained as previously described [15]. 
Briefly, cells were rinsed twice with ice-cold phosphate-
buffered
  saline and collected on ice in phosphate-buffered 
saline containing
 1 mM EDTA, scraped and pelleted
 by cen-
trifugation. Cell pellets were resuspended
 in ice-cold hypo-
tonic buffer (10 mM HEPES [pH 7.9], 10 mM potassium
 
chloride, 1.5 mM magnesium chloride, 0.5 mM dithiothrei-
tol,
  0.2 mM phenylmethylsulfonyl fluoride, 1 g of leu-
peptin/ml,
 1 g of pepstatin A/ml), immediately repelleted, 
resuspended again in ice-cold hypotonic buffer, and allowed 34    The Open Virology Journal, 2007, Volume 1  Baldwin et al. 
to swell on ice for 10 min.
 Nuclei were obtained by centrifu-
gation (1,500 x g, 10 min, 4°C)
 following disruption of the 
cells with a Dounce-type mortar
 and pestle and then resus-
pended in extraction buffer (250 l/20
  100-mm-diameter 
tissue culture dishes; 20 mM HEPES [pH 7.9],
 0.5 M potas-
sium chloride, 1.5 mM magnesium chloride, 0.2 mM
 EDTA, 
25% glycerol, 0.5 mM dithiothreitol, 0.2 mM phenylmethyl-
sulfonyl
  fluoride, 1 g of leupeptin/ml, 1 g of pepstatin
 
A/ml) by gentle pipetting. Nuclear proteins were extracted 
by
 gentle rocking (30 min at 4°C) followed by centrifugation
 
(16,000 x g, 30 min, 4°C). The supernatant containing the
 
nuclear extract was dialyzed for 45 min on ice with gentle 
stirring in 100 ml (400 volumes)
 of ice-cold dialysis buffer 
(20 mM HEPES [pH 7.9], 0.1 M potassium
 chloride, 0.2 mM 
EDTA, 20% glycerol, 0.5 mM dithiothreitol,
 0.2 mM phen-
ylmethylsulfonyl fluoride), and precipitates
 were removed by 
centrifugation (16,000 x g, 20 min, 4°C). 
  Electrophoretic Mobility Shift Assays (EMSAs). EM-
SAs were performed as described previously [15]. Double-
stranded oligonucleotides representing all 7 NFI half sites, 
between 20 and 25 bases
 in length (Fig. 2A), were 5' end 
labeled and used as probes. HKc/HPV16 nuclear
 extracts (12 
g of protein) were incubated with 10-fold-concentrated 
binding buffer (100
 mM Tris-HCl [pH 7.5], 0.5 M sodium 
chloride, 10 mM dithiothreitol,
  50% glycerol), 1 g of 
poly(dI · dC),
 0.5 g of sonicated herring sperm DNA, and 
125-fold unlabeled
 specific or non-specific oligonucleotides 
(as competitors to determine
 binding specificity) in a final 
volume of 10 l for 15
 min on ice. Probe (100 ng) was added 
to each reaction mixture
  and allowed to incubate at room 
temperature for an additional
  15 min. The entire reaction 
mixture was loaded without dye and
 resolved on a 5% non-
denaturing Tris-glycine polyacrylamide gel
 (2.5 h at 150 V). 
Gels were dried and visualized using a Bio-Rad
 K-screen and 
phosphorimager. 
  Plasmid Constructs and Mutagenesis. A luciferase 
reporter vector under control
  of the HPV16 URR 
(pGL3/URR) was constructed by cloning the entire
  URR 
(Fig. 1) into the HindIII multiple cloning site of pGL3-basic
 
(Promega), as described previously [15]. For NFI mutational 
analysis, mutant constructs were created using the
  Quick 
Change site-directed mutagenesis kit (Stratagene) by intro-
ducing point
  mutations in single and multiple NFI site(s) 
(GCCAA changed to GCAGA which is unable to bind NFI). 
For NFI enhancer analysis, enhancer elements containing 5 
consensus or mutant NFI half sites, each separated by 10 
random nucleotides (Fig. 4), were synthesized. These ele-
ments were cloned upstream of the CMV promoter / lu-
ciferase gene (pGL3 promoter, Promega). All constructs 
used were verified by sequencing. 
  Transfections and Luciferase Assay. Transfections and 
luciferase assays have been described previously [15]. Plas-
mid constructs were transfected, in triplicate, into 
HKc/HPV16 cultured in 60-mm-diameter dishes at 30 to 
40% confluency
  by using Transfast (Promega). To control 
for variations
 in transfection efficiencies (which ranged from 
10 to 30%), the triplicate plates were trypsinized,
  and the 
cells were pooled and replated onto six 60-mm-diameter
 
dishes 12 to 15 h posttransfection. Luciferase activity was 
determined
  68 to 72 h posttransfection with the luciferase 
assay system
  (Promega). Experiments were performed at 
least three times,
 and each construct was tested in triplicate 
dishes. Relative
  light units were determined using a lumi-
nometer (Berthold Lumat
  LB9501). Background luciferase 
activity was determined by transfection with pGL3-basic 
alone. 
RESULTS AND DISCUSSION 
  Binding to the NFI Sites of the HPV16 URR. To inves-
tigate the binding of cellular factors to the NFI sites of the 
HPV16 URR (schematic shown in Fig. 1), oligonucleotides 
representing all 7 NFI half sites were constructed (Fig. 2A) 
and used as probes in electrophoretic mobility shift assays 
(EMSAs) (Fig. 2B). Nuclear extract from HPV16-
immortalized human keratinocytes (HKc/HPV16) was ob-
tained and incubated with each probe. Cold competitor probe 
was added to determine specific NFI binding (lane 9, Fig. 
2B), and free probe was separated from probe·protein com-
plexes (Fig. 2B). The presence and the location of NFI bind-
ing were previously verified and reported using NFI sites #2 
and #3 in supershift analysis using NFI antiserum (provided 
by Dr. Naoko Tanese) [15]. 
  Binding to the NFI sites of the HPV16 URR varied in 
pattern and intensity (Fig. 2B). A smear of NFI binding can 
be seen for NFI sites #2 and #3, and to a lesser extent for site 
#1 (Fig. 2B lanes 2, 3 and 4). Very little binding, however, 
was observed for NFI site #7 (Fig. 2B lane 8). NFI sites #4, 
#5 and #6 showed a reduced, varied pattern of binding (Fig. 
2B lanes 5-7), which is likely due to the close proximity of 
multiple transcription factor binding sites. For example, Tef-
1 binding sites are adjacent to NFI sites #4 and #6, and there-
fore may include Tef-1 in the protein complex. These results 
demonstrate that binding to all NFI sites of the HPV16 URR 
is not equal, suggesting that the relative contribution of each 
NFI site to early gene expression may differ. 
  Mutational Analysis of HPV16 URR NFI Binding 
Sites. A mutational analysis of the NFI sites was performed 
to determine the role of the 7 NFI sites in transcription of the 
HPV16 early genes. Point mutations of single and multiple 
NFI sites were introduced within the context of the entire 
HPV16 URR, cloned upstream of a luciferase reporter gene. 
Mutation of NFI sites #1 and #5 had very little effect on ba-
sal activity of the HPV16 URR, while constructs containing 
mutations to either NFI site #4 or NFI sites #2 and #3 re-
duced the basal activity of the promoter to less than 20% 
(Fig. 3). All constructs containing mutations to at least 5 NFI 
binding sites retained less than 1% of basal activity (Fig. 3). 
Although these 3 constructs lost over 99% of basal activity, 
measured RLU values were still 3 to 5-fold greater than 
those obtained from transfection with pGL3-basic alone. 
  Previous mutational analysis of NFI binding sites of the 
HPV16 URR involved cloning 91 bp fragments of the 
HPV16 URR containing NFI sites #2 and #3, or NFI sites #4 
and #5 upstream of the TK promoter / CAT reporter and 
transfection into HeLa cells [17]. This analysis revealed that 
these 4 NFI sites were important for enhancer activity, to 
varying degrees. Mutation of NFI site #4 reduced relative 
activity to 15.8%, which mirrored our results for the NFI site 
#4 mutant (Fig. 3). However, our mutational analysis of NFI 
sites #2, #3, and #5 did not concur with this previous study. 
This may be due to the fact that our mutational analysis was 
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use of additional promoters, or that the previous analysis was 
carried out in HeLa cells, while ours were performed in 
HPV16-immortalized keratinocytes. 
  The relative amount of NFI binding observed for each 
site correlated somewhat to the importance of that particular 
binding site to basal activity of the promoter. For example, 
NFI sites #2 and #3 showed a relatively large amount of 
binding (Fig. 2B lanes 3 and 4), and upon mutation of those 
NFI sites, basal activity of the promoter was reduced by 81% 
(Fig.  3). Conversely, when NFI sites were mutated that 
showed a lesser amount of binding (sites #1 and #5, Fig. 2B 
lanes 2 and 6), the basal activity of the promoter was reduced 
by only 15% (Fig. 3). An exception to this trend was NFI site 
#4. This site demonstrated a relative reduced level of binding 
(Fig. 2B lane 5); however, the basal activity of the promoter 
was reduced by 83% upon mutational analysis (Fig. 3). Col-
lectively, these data reveal NFI to be a crucial transcription 
factor for HPV16 URR basal activity. The contribution of 
each NFI binding site, however, is not equal. 
  NFI Binding Sites as an Enhancer. It was previously 
reported that a cell-type-dependent regulatory element 
(CTRE), a 178 bp element containing NFI sites #1 to #3 (nt 
7454 to 7632), is necessary for full enhancer activity in an 
HPV-immortalized keratinocyte cell line [16]. To determine 
whether NFI could act as an enhancer in the absence of 
HPV16 URR sequences, we synthesized enhancer elements 
containing 5 consensus or mutant NFI half sites, each sepa-
rated by 10 random nucleotides (Fig. 4). These elements 
were cloned upstream of the CMV promoter / luciferase 
gene (pGL3 promoter, Promega), the resulting constructs 
were transfected into HKc/HPV16, and luciferase activity 
was measured 70 h post transfection. The NFI enhancer pro-
duced a 4-fold increase in luciferase activity (Fig. 4),  
 
 
Fig. (1). NFI binding Sites of the HPV16 URR. The central keratinocyte dependent enhancer (KDE), and the 3’ and 5’ segments of the 
HPV16 URR are shown. The location of each NFI half site within the KDE is noted. The sequence for the HPV16 URR KDE is given, with 
the 7 NFI binding sites bolded and underlined. 
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CCCTGTTTTC CTGACCTGCA CTGCTTGCCA ACCATTCCAT TGTTTTTTAC 
ACTGCACTAT GTGCAACTAC TGAATCACTA TGTACATTGT GTCATATAAA 
ATAAATCACT ATGCGCCAAC GCCTTACATA CCGCTGTTAG GCACATATTT 
TTGGCTTGTT TTAACTAACC TAATTGCATA TTTGGCATAA GGTTTAAACT
TCTAAGGCCA ACTAAATGTC ACCCTAGTTC ATACATGAAC TGTGTAAAGG 
TTAGTCATAC ATTGTTCATT TGTAAAACTG CACATGGGTG TGTGCAAACC
NFI #1
NFI #2
NFI #3
NFI #6 NFI #5
NFI #4
NFI #7
7461
7761
7661
7561
786036    The Open Virology Journal, 2007, Volume 1  Baldwin et al. 
compared to the CMV promoter alone. This increase was not 
observed for the mutant NFI enhancer element (Fig. 4), 
demonstrating that NFI enhancer function does not necessar-
ily depend on other sequence elements located in the HPV16 
URR. 
  The possibility that NFI requires a co-activator(s) for 
expression in epithelial cells has been previously proposed 
[17]. Exogenous NFIC was found to activate HPV16 enhan-
cer fragments in NFI deficient SL-2 (insect) cells. However, 
this activation did not take place in fibroblasts, implying that 
a necessary co-activator was absent in fibroblasts [17]. Our 
data suggest that if a co-activator is necessary for enhancer 
function, it does not require elements within the URR for 
binding. Additionally, Oct-1 has been shown to activate 
epithelial-specific enhancer activity of HPV16 by interaction 
with NFI site #6 at a conserved, composite element in HeLa 
cells, dependent upon both the binding site for NFI and an 
adjacent site able to bind Oct-1 [18]. While it is not our in-
tention to rule out the influence of positive co-activators, our 
results do imply that other URR binding sites are not neces-
sary for anchorage or stabilization of NFI co-activator(s), 
and that the stereospecificity contributed by adjacent tran-
scription factor binding elements in the HPV16 URR must 
not be crucial for the enhancer function of NFI. The apparent 
contradiction between our study and previous studies [17, 
18] may be due to cell-type specific co-activator(s) and / or 
the physiological state of the cell. Interestingly, in light of 
our binding and mutational analysis, negative regulatory 
elements located near NFI binding sites in the HPV16 URR 
likely contribute to reduced NFI binding (Figs. 2 and 3) as 
binding to NFI sites #1 and #5 is minimal (Fig. 2B, lanes 2 
and 6), and mutation of those 2 sites produces only a small 
decrease in basal activity of the HPV16 URR. 
  This work supports previous reports that NFI is an impor-
tant positive transcription factor for the activity of the 
HPV16 URR [7, 11, 16-19]. This is the first study however, 
 
Fig. (2). Binding to NFI Sites of the HPV16 URR. (A) Double stranded oligonuclotides representing the 7 NFI half sites of the HPV16 URR 
were labeled as probes and used in electrophoretic mobility shift assays (EMSAs). The nucleotide sequence for each probe is shown. (B) 
Nuclear extract (12 g of protein) from HKc/HPV16 was incubated with each probe. Protein-probe complexes were separated from the free 
probe on a 5% non-denaturing polyacrylamide gel. Specific NFI binding as well as non-specific (NS) binding is noted. Addition of cold 
competitor (125X) illustrates specific NFI binding (lane 9). 
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to demonstrate the role and relative contribution of each NFI 
site to HPV16 early gene expression. This mutational analy-
sis, conducted in the context of the entire HPV16 URR, is 
strongly supported by our NFI binding data. We also demon-
strate here that NFI binding sites do comprise strong enhan-
cer function in HPV16-immortalized human keratinocytes, 
in the absence of other URR elements. Collectively, these 
results demonstrate that NFI is an essential positive tran-
scription factor for HPV16 URR activity. 
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